A Phase II trial combining O6-benzylguanine with Gliadel wafers, or carmustine implants that deliver local chemotherapy, showed efficacy in patients with recurrent GBM, although patients were not stratified on MGMT status (146). Here, MGMT is linked to glioblastoma.